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Abstract Natural killer (NK) cells play a critical role in
viral immunity. In the setting of HIV infection, epidemi-
ologic and functional evidence support a role for NK cells
in both protection from new infection and in viral control.
Specifically, NK cells directly mediate immune pressure
leading to virus evolution, and NK cell receptor genotypic
profiles, clonal repertoires, and functional capacity have
all been implicated in virus containment. In addition, in-
direct NK cell-mediated antibody-dependent cellular cyto-
toxicity has been linked to vaccine-induced protective im-
munity against HIV infection. With recent advances in our
understanding of NK cell deficiency, development,
memory-like responses, and editing of the adaptive im-
mune system, the opportunities to direct and exploit NK
cell antiviral immunity to target HIV have exponentially
grown. In this review, we seek to highlight the intersec-
tions between discoveries in basic NK cell biology and
the challenges of HIV chronic infection, vaccine develop-
ment, and cure/eradication strategies.
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Introduction
Natural killer (NK) cells occupy a unique niche in the immune
response, bridging the innate and adaptive immune systems.
They are capable of recognizing generic signals of stress,
transformation, or infection with immediate effector function.
NK cells are the critical antiviral effectors of the innate im-
mune system, and natural deficiencies are associated with sus-
ceptibility to viral infections [1, 2]. However, there is still a
nascent understanding of their pleiotropic functions as direct
effectors, but also as editors of adaptive immunity in both
infection and vaccination [3]. Recent work has also highlight-
ed the adaptive features of NK cells that can confer a memory-
like phenotype in the setting of infection [4]. NK cells have the
potential to directly respond to viruses, to develop memory-
like responses after initial pathogen encounter or vaccination,
and to shape the adaptive immune response (Fig. 1).
As the understanding of NK cell biology grows, there are
promising avenues to address several current challenges in
HIV: development of an effective vaccine, control of residual
inflammation in treated disease, and emerging strategies for
eradication or cure. NK cell deficiency syndromes have re-
vealed specific developmental programs that shape the mature
NK cell population and can broadly modulate responses [5].
The HIV vaccine literature has identified the critical impor-
tance of antibody-dependent cellular cytotoxicicty (ADCC),
mediated predominantly by NK cells, via non-neutralizing
antibodies as a pathway to protective vaccine responses [6].
Importantly, these ADCC responses are associated with
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specific immunoglobulin subclasses [7] and glycan modifica-
tions that directly impact the efficiency of NK cell responses
[8, 9]. This affords multiple avenues for optimization of anti-
bodies to maximize NK cell function for preventative and
therapeutic vaccination [10].
The profile of NK cell responsiveness beyond CD16-
mediated antibody recognition also points to anti-HIV
function. High dimensional characterization of the combi-
natorial diversity of NK receptor expression offers new
insights into the phenotypic features of protective NK cell
responses and how they may be directed [11, 12••].
Building on prior work showing antigen specificity in
mouse models, recent studies have demonstrated NK cell
memory responses to simian immunodeficiency virus
(SIV) antigens in nonhuman primates, suggesting a path-
way to induce antigen-driven memory in humans [13••].
In line with recent findings in the myeloid compartment
delineating the phenomena of innate training and tolerance
[14], unique epigenetic signatures in NK cells primed by
cytomegalovirus (CMV) infection demonstrate how NK
cells can be programmed by an initial pathogen (or poten-
tially vaccine) exposure [15••, 16••]. Taken together, this
work suggests infection can shape the NK cell repertoire
and alter subsequent responses; a detailed understanding of
this functional plasticity will inform efforts to develop
preventative and therapeutic vaccines against HIV.
Fig. 1 Multiple facets of NK cell biology can be harnessed towards the
goal of HIV prevention and eradication. (Right panel) NK cells can
directly recognize HIV-infected targets through expression of stress
ligands on infected cells or potentially through antigen-specific
responses as has been demonstrated in the SIV infection in rhesus
macaques. This recognition may lead to degranulation and target cell
cytolysis. In addition, secretion of chemokines such as MIP-1β can
block new rounds of infection and effectors such as IFNγ can activate
antiviral programs. (Bottom panel) NK cells can also be indirectly
recruited to HIV-infected cells through CD16 engagement of the Fc
receptor of antibodies bound to HIV epitopes. Optimization of these
antibodies through subtypes with multiple coordinated activities and
glycan patterns that direct maximal responses can enhance NK effector
function. (Left panel) NK cell cross-talk with the adaptive immune
system also affords opportunities for modulating responses. NK cells
edit T follicular helper (TFH) cells altering germinal center formation
and antibody development through cross-talk with B cells. TFH cells are
also a reservoir of HIV infection, and could potentially be targeted by NK
cells in early infection or during curative interventions. NK cell editing of
CD4+ T cell responses also contributes to immune exhaustion in chronic
viral infection models, and limits immunopathology in acute infections
that are cleared. There is the potential for bidirectional effects with NK
cell limiting or enhancing CD4 function, and CD4 T cell cytokine
production supporting improved NK cell effector capacity. In sum,
there are multiple avenues through which NK cell function can be
leveraged to optimize immune responses to HIV
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In this review, we discuss the role of NK cells in the im-
mune response to HIV in the context of recent advances in NK
cell biology, highlighting opportunities to harness these innate
cytolytic effector cells for the rapid containment and clearance
of HIV.
NK Cells in HIV Infection
The Role of NK Cells in the Immune Response to HIV
Infection
Population-level genetic associations between NK cell recep-
tor expression and HIV-1 outcomes and evolution reveal the
impact of NK cells on HIV-1 disease progression. The
germline encoded inhibitory receptors including the killer
immunoglobulin-like receptors (KIRs) heavily influence NK
cell activation which is governed by the integration of activat-
ing and inhibitory signals. Interactions between KIRs and
their cognate HLA ligands set a threshold for NK activity
and have been shown to critically influence the course of viral
infection, associating with resolution of hepatitis C infection
[17]. In HIV, HLA/KIR combinations have been associated
with the pace of disease progression [18, 19] and protection
against disease acquisition [20, 21]. The mechanisms confer-
ring this protection may include both NK cell education/
licensing through inhibitory receptor ligation [22] and the di-
rect interaction of KIRs with HIV-1-derived peptide motifs
presented on HLA molecules. The latter is supported by virus
evolution in the presence of specific KIRs; footprints in the
HIV genome associate with KIR genotype. Specific viral
variant/KIR combinations associate with differences in NK
cell viral inhibition in vitro [23] and HLA/KIR combinations
confer differences in HIV control [24]. The HLA/KIR inter-
actions directed by specific HIV-derived peptides are further
linked to measures of NK cell function in vitro and patterns of
viral escape in population studies [25, 26]. These data suggest
that NK cell activation threshold, determined in part by the
genetic array of inhibitory receptors, and the virus-derived
peptides available for presentation on host HLA cooperate to
define the protective efficacy of NK cell responses. The latter
could be exploited to harness function; computation ap-
proaches may be able to predict peptides that modulate NK
function based on host HLA/KIR patterns to individualize
vaccine design.
These data demonstrate direct interactions between NK
cells and HIV peptides; however, it is not known whether
these signals govern in vivo effector function and which of
the overlapping recognition pathways is sufficient for an ef-
fective response. Although counterintuitive, focusing on im-
mune responses that HIV has evolved to evade may point to
highly effective means of NK activation. HIV-mediated
downregulation of HLA molecules, which shields infected
cells from killing by CD8+ T cells [27], theoretically offers
the “missing self” trigger for NK cells. However, this is lim-
ited by HIV immune evasion; the downregulation of HLA A
and B by Nef is coupled to preservation of HLA C and E,
maintaining self signals, and preventing NK activation [28].
Likewise, HIV infection directly triggers the upregulation of
stress ligands for cytotoxicity receptors including NKG2D
[29, 30]. Again, HIV is able to limit expression of these li-
gands and other coactivating signals such as NTBA-4 through
accessory proteins [29, 31]. While the precise contribution of
each activation pathway in natural infection is difficult to
prove, from the perspective of prevention and cure, each could
be leveraged to optimize responses. Small molecule inhibitors
disabling immune evasion through viral accessory proteins
may enhance native or vaccine-induced immune recognition.
ADCC is a potent means of NK cell control of HIV-1
infection. NK cells express the FcγRIIIA receptor (CD16) that
binds the constant (Fc) domain of IgG antibodies. CD16 en-
gagement is a strong activator of NK cell function, and allows
antigen-specific recruitment of NK responses. Importantly,
ADCC activity was associated with the modest protective ef-
ficacy in the RV144 HIV vaccine trial [6] and has been impli-
cated in phenotypes of viral control [32, 33]. Responses char-
acterized by coordinated antibody function, including NKme-
diated ADCC and NK cytokine secretion/degranulation asso-
ciated with viral controller phenotypes [34]. ADCC efficiency
is linked to specific antibody features including subclass and
glycosylation that can be modified to enhance NK cell recruit-
ment and activation. NK cell maturation and education can
further enhance HIV-specific ADCC activity [35, 36]. Of note,
as with other effector pathways, ADCC is also limited by viral
evasion: the viral accessory protein Vpu antagonizes the anti-
viral factor tetherin, altering the release of virus aggregates
and disabling ADCC mediated viral recognition [37–41]. A
small molecule inhibitor of vpu’s interaction with tetherin has
recently been described suggesting an additional target for
intervention [42]. An optimized approach would prime NK
cells, induce antibodies with glycan and subclass features
maximized for ADCC and could potentially be coupled with
pharmacologic blockade of viral immune evasion to further
enhance antiviral function.
The collective data highlight the importance of NK cells in
HIV disease. There are multiple pathways for target elimina-
tion, all balanced by mechanisms of viral evasion that define
kinetic windows of maximal response and opportunities for
enhancement. In addition to these specific interactions, NK
cell recognition of generic signals of stress and infection in-
duced early in HIV infection is an important area for explora-
tion. Optimized NK cell function can be achieved through
directly augmenting NK cell function with priming and subset
expansion or inhibitory receptor blockade, indirectly through
optimization of antibodies to recruit NK cells, and potentially
also through blockade of viral accessory proteins to limit im-
mune evasion.
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The Consequences of HIV Infection for NK Cell Distribution
and Function
Chronic HIV-1 infection alters the population distribution and
functional capacity of NK cells. Numerous studies have de-
scribed these changes in the setting of HIV infection and have
at times produced diverging and contradictory results. This
lack of clarity is likely related to multiple factors: the depen-
dence of NK cell function on the associated HLA genotype
has not always been fully considered, many studies are cross
sectional in nature and may not have adequately controlled for
confounders between groups including CMV serostatus, age,
and gender, and finally the diversity of NK cell phenotypes is
not fully captured in a limited examination of markers [11,
12••].
NK cells are divided into subsets based on their expres-
sion of CD56 and CD16; these subsets are thought to
represent stages in NK cell differentiation, although the
precise relationship has not been fully defined. Based on
immunodeficiency syndromes, both CD56bright and
CD56dim populations contribute to antiviral immunity.
CD56brightCD16− cells are a minor population in healthy
individuals with relatively limited cytotoxic capacity but
strong production of cytokines. CD56dim NK cells are the
majority of the circulating population with less prolifera-
tive potential, increased cytotoxic capacity, and progres-
sive acquisition of KIRs and markers including CD57
during differentiation. A third minor population is the
CD56neg NK cells that are CD16+; these cells have been
difficult to characterize with their limited expression of
lineage markers. NK cells express a broad complement
of additional receptors including the predominantly inhib-
itory KIRs; the natural cytotoxicity receptors (NCRs) in-
cluding NKp30, NKp44, and NKp46; the C-type lectin
receptors including NKG2D, NKG2C, and NKG2A; sig-
naling lymphocyte activation (SLAM) family receptors as
wel l as the Fcγ receptor CD16 [43] . NK ce l l
degranulation/cytotoxicity and cytokine secretion are
governed by the overall balance of activating and inhibi-
tory signals, with an important role for education through
inhibitory signaling during development [44]. The roles of
each subset in HIV-1 infection are still being defined.
During primary HIV infection, initiation of antiretro-
viral therapy was associated with reciprocal variation in
the CD16+CD56dim and CD56high NK cells, with the lat-
ter, more immature population, increasing after therapy
[45]. Initiation of therapy also changes immunoregulato-
ry markers; modulation of galectin 9 and T cell immu-
noglobulin and mucin-domain containing molecule-3
(TIM-3) in early infection leads to enhanced NK cell
activity, but in chronic HIV the interaction may contrib-
ute to NK cell dysfunction [46]. Dysregulated TIM-3
expression on NK cells is linked to impaired CD4
recovery after treatment, suggesting that NK cell dys-
function may contribute to a poor immunologic reconsti-
tution in some individuals [47]. CD56negCD16+ cells
with reduced ADCC activity also accumulate during
chronic infection, a defect that is significantly restored
with viral suppression [48, 49]. Counterbalancing this
restoration of NK cell ADCC is the decline in antibody
conferred activity after initiation of antiretroviral therapy
(ART) [50]. Thus, to fully exploit the potential for NK
cell-mediated function in cure/eradication strategies
through ADCC, restoration of subset distribution is an
essential step, beyond optimizing antibody subclass, gly-
can structure and titer through vaccination or administra-
tion of a monoclonal.
In vitro studies have sought to dissect receptor patterns
that lead to NK cell control of HIV infection. When ex-
posed to infected CD4+ T cells, autologous NK cells ex-
pressing NKG2A responded with CD107a (a marker of
degranulation), IFNγ, and CCL4 at the highest frequen-
cies [51]. Profiling the NKG2A receptor expression in an
individual may offer an index of their likelihood to have
an effective NK cell response to a therapeutic interven-
tion. In the setting of significant inflammation in a cohort
in Uganda with HIV subtype D infection, impaired effec-
tor function (IFNγ production) and loss of a highly acti-
vated subset of NK cells has been described [52]. Further
evidence of dysfunction is suggested by studies in the SIV
nonhuman primate model demonstrating anergic NK cell
accumulation in lymph nodes in chronic infection [53].
Research to redirect or rescue function will be informed
by the more complete understanding of the pathology of
HIV. An alternative window to identify highly effective
activation pathways may be through the enhanced effector
capability seen in NK cells from individuals with sponta-
neous viral control. One recent example is the recent re-
port of a potential role for NK cells in the long-term
suppression of HIV-1 in the VISCONTI cohort of post-
treatment controllers (Scott-Algara, et al., Abstract 15,
CROI 2015, Seattle, WA).
In support of the concept that NK cells can be direct-
ed, methods of bolstering NK cell functional capacity in
HIV infection have been described. A therapeutic HIV
vaccine that restored CD4+ T cell IL-2 production led to
enhanced production of IFNγ by NK cells [54]. Secretion
of IFNα by other cells drives NK cell activation and lysis
of HIV-infected CD4+ T cells through NKp46- and
NKG2D-mediated signaling [55]. The cross-talk between
adaptive and NK cell responses is a critical means for
optimizing NK cell function. Coordinating the recruit-
ment and activity of multiple cell types, particularly in
the setting of an inflamed and anergic immune system,
may be the key to promoting more effective NK cell
control of HIV.
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NK Cell Development
Genetic Determinants of NK Cell Deficiency Syndromes
Naturally occurring NK cell deficiency syndromes offer
important insights into the biology of these cytolytic ef-
fectors. Deficiency syndromes are broadly divided into
classical NK cell deficiency (CNKD) with numeric and
functional deficits, and functional NK cell deficiency
(FNKD) in which cells are present but poorly functional
(reviewed in [5, 56]). Genetic defects associated with both
types of syndrome have been identified. In CNKD1, mu-
tations in the transcription factor GATA2 confer deficits in
peripheral NK cell numbers and function, with marked
susceptibility to viral infections (varicella zoster virus,
herpes simplex virus, cytomegalovirus, human papilloma
virus) and mycobacterial infections. These patients specif-
ically lack of the CD56bright subset and show globally
impaired expression of NKG2D [57]. A distinct syn-
drome, CNKD2, is linked to a mutation in MCM4, with
a converse phenotype of absence of the CD56dim popula-
tion with clinical findings of recurrent viral infections and
EBV-driven lymphoproliferative disorders [58]. The defi-
cit in opposite subsets in these two syndromes is striking
given their proposed developmental relationship and the
susceptibility to viral infections seen in both patient
groups. In a separate patient cohort with marked suscep-
tibility to herpesvirus infections and a form of FNKD,
studies identified a mutation in the membrane distal do-
main of CD16. This mutation abrogated an interaction
between CD16 and CD2, preventing activation of sponta-
neous cytotoxicity responses despite preserved ADCC
[59]. The efficiency of ADCC responses is also associated
with control of herpes simplex virus (HSV). Higher affin-
ity allotypes of CD16 and IgG are linked to control of
HSV (versus recurrent outbreaks) and are associated with
enhanced ADCC in vitro [60, 61]. Multiple additional
genetic loci have been linked to deficiencies in NK cell
number and function in combined immune deficiency
syndromes [62].
Taken together, these findings highlight key functional
and developmental aspects of NK cell biology. First, both
the CD56bright and CD56dim populations have significant
roles in control of virus infections. Second, expression of
CD16 has dual significance, promoting cytotoxic activity
triggered by CD2 ligation as well as mediating ADCC.
Third, the efficiency of the ADCC response is associated
with successful control of herpes virus, reinforcing the role
of ADCC in phenotypes of elite control in HIV. These
observations may inform some of the disruption seen with
shifts in the CD56 expression with chronic HIV infection,
and supports the pursuit of both direct antiviral and
ADCC strategies in HIV eradication and cure efforts.
Homeostasis and Maturation Signals
Given the defects seen in chronic HIV infection, under-
standing key differentiation signals in NK cell biology
may point to therapeutic strategies to shape or direct
their responses. IL-15 is a master regulator of NK cell
maturation, survival, and functional competence. IL-15
preferentially expands cytotoxic NK subsets, with less
proliferative stimulus for regulatory T cells than IL-2,
shifting the net balance towards activation [63]. Recent
human clinical trials in patients with metastatic cancer
have demonstrated proliferation and activation of NK
cells after administration of recombinant human IL-15
[64••]. In this exploratory study, no objective remissions
were achieved; however, there was preliminary evidence
of immune activity seen in the clearance of lung lesions
in two of the subjects [64••]. This particular approach is
relevant to HIV cure strategies; enhancing innate sur-
veillance by NK cells in concert with latent virus reac-
tivation can circumvent limitations of traditional adap-
tive responses to HIV. Ongoing efforts to optimize de-
livery methods (e.g., with heterodimeric formats of the
cytokine and a receptor subunit [65]) and synergistic
combinations of cytokine with antibody or effector
CTLs are active areas of investigation (Euler, Jones,
and Alter, in preparation). In a humanized mouse model
of HIV infection, use of an IL-15 superagonist (IL-15
bound to the soluble IL-15Rα) effectively blocked HIV
infection, in an NK cell dependent manner [66]. In par-
allel to these studies, multiple clinical trials of adoptive
therapy with expanded allogeneic NK cells in cancer are
assessing the therapeutic potential of ex vivo expansion
and reinfusion into patients [67]. Results of these trials
will be critical to define the safety of NK cell expansion
and administration and may inform which subsets are
critical to immune protection. Both of these approaches,
in vivo exposure to IL-15 and ex vivo NK cell manip-
ulation and reinfusion, have potential advantages, and
further work is needed to define the most promising
avenues.
Multiple additional pathways to modulate NK cell mat-
u ra t ion and func t ion are under inves t iga t ion .
Immunomodulatory therapies have potential efficacy in
NK cells analogous to the effects described for the adaptive
immune system; blocking PD-1 on NK cells from multiple
myeloma patients enhanced killing of autologous tumor
cells [68]. Indirectly, proteasome inhibitors used in cancer
chemotherapy also enhance NK cell function, at least in
part by downregulation of HLA molecules triggering miss-
ing self responses [69]. Due to their highly potent cytotoxic
activity, an array of inhibitory receptors tonically repress
the function of NK cells [44], offering another target for
intervention. Direct blockade of inhibitory KIR receptors
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has been shown to augment spontaneous NK cell cytotox-
icity in animal models [70] and is in exploratory clinical
trials of cancer therapy [71].
NK Cell Activation and Specificity
Efforts to modulate NK cells with cytokines and direct thera-
pies point back to a critical question in NK cell biology. While
there is considerable variation in NK cell response potential,
the precise determinants (e.g., receptor expression and matu-
ration state) of an NK cell response to pathogen challenge are
not clear. In contrast to adaptive immune responses that are
governed by antigen-specific gene-rearranged receptors, NK
cells integrate multiple activating and inhibitory signals to
reach a threshold of activation. Importantly, both the KIR
genotype of an individual [22] and the multiple unique com-
binations of receptors that can be expressed [11, 12••] contrib-
ute to the NK population diversity of receptor expression and
activation potential. However, apart from the genetic determi-
nants, environmental and stochastic factors including infec-
tious exposures such as CMV are also capable of profoundly
shaping the response potential of NK cells through alterations
in repertoire distribution [72, 73]. Building on differences in
surface receptors, work defining transcriptional signatures of
NK cells in distinct activation states has provided a context to
understand NK cell activation alone and in relationship to
innate lymphoid cells and traditional T cells [74]. Moving
forward, to truly harness NK cells towards a therapeutic goal,
the determinants of NK cell repertoire composition, activation
threshold, and role in susceptibility to infection must be
defined.
NK Cell Repertoire Diversity
Detailed studies with high dimensional analysis enabled by
cytometry by time of flight (CyTOF) has provided novel in-
sights into the diversity and specificity of the NK cell reper-
toire [11, 12••]. These studies reveal the potential for NK cell
combinatorial receptor diversity, with estimates of up to 30,
000 unique receptor phenotypes on a single NK cell in an
individual subject. Remarkably, most individual receptor
combinations contributed to only a minority of the overall
NK cell population, with only the less mature NKG2A+/
CD94+ NK cells and more mature CD57+/CD16+ population
as primary distinct phenotypes [11]. Distinct responses to
stimuli, proliferative potential, cytokine production, and cyto-
lytic activity are seen in subsets defined by the expression of
CD57 [75]. Diversity of phenotypes in adults is correlated
with CD57 expression, suggesting that maturation leads to
divergence, and was associated with risk of HIV acquisition.
In case control analyses of high-risk women, increased NK
cell diversity was associated with an increased probability of
HIV-1 infection [12••]. It is not clear whether the NK diversity
reflects a “distraction” from the challenging pathogen that
increases susceptibility or if it is linked to other immune char-
acteristics such as Tcell exhaustion. These data raise questions
about preventative and therapeutic vaccination goals; a naïve
repertoire may have more flexibility and protective potential
than one directed at other pathogens; however, a vaccine-di-
rected, pathogen-specific response should be superior to both.
Understanding how clonal NK cell populations can be
reshaped and directed will critically inform the potential to
harness a range of biological functions of NK cells through
vaccine design.
NK Cell Memory
While classically considered as nonspecific innate effector
cells, there is growing data to support adaptive, memory-like
features of NK cells. These features can be divided into two
categories, antigen-specific responses with classical recall
characteristics and a more general alteration in effector func-
tion conditioned by an infection, vaccination, or inflammatory
environment in line with the phenomenon of innate training in
the myeloid compartment [14, 76]. Both types of memory
responses are potential targets for immune intervention.
The mouse model of hapten-mediated contact hypersensi-
tivity reactions provided the first demonstration of persistent,
antigen-specific, and transferrable memory in NK cells [77].
Further work identified the importance of the chemokine re-
ceptor CXCR6 in memory development and extended the
observations from haptens to influenza virus-like particles
and inactivated vaccinia virus; the receptors mediating this
recognition have remained undefined [78]. The first report
of NK cell memory in the setting of a viral infection demon-
strated NK cell-mediated responses to mouse cytomegalovi-
rus (MCMV) [79]. Development of murine CMV (MCMV)
memory was linked to interactions between the NK receptor
LY49H and the viral glycoprotein m157 [80, 81], and memory
cells were broadly distributed in the tissues, in contrast to the
liver-resident hapten-directed memory cells [79].More recent-
ly, memory NK cells specific for SIVantigens have been iden-
tified in the nonhuman primate model [13••]. NK cells derived
from rhesus macaques infected with SIVor a virus combining
SIV and HIV (SHIV) showed antigen-specific killing of tar-
gets pulsed with HIV protein components, and a persistent
response to vaccine antigens was identified in animals who
had received an adenovirus 26 (Ad26) vectored SIV vaccine
5 years earlier [13••]. These memory NK cells were elicited by
both vaccination and infection, were durable and specific, and
were recovered from both the liver and spleen [13••]. These
animal model data demonstrate antigen-specific NK cell
memory and while direct evidence in humans is lacking, these
studies strongly support efforts to identify and harness this
activity in human disease. Access to the relevant cell popula-
tions, e.g., hepatic or splenic cells, may be critical to identify
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these responses and should be one focus of study. In parallel,
in vitro studies to induce memory-like response and animal
models including the humanized mouse offer additional op-
portunities to explore the biology of these cytolytic effectors.
Antigen-specific memory in NK cells has clear parallels to
traditional adaptive immunological memory. Consistent with
their unique role bridging the innate and adaptive responses,
NK cells are also capable of a memory phenotype that is
induced by more generalized signals. Exposure of murine
NK cells to cytokines (IL-12, IL-15, and IL-18) in vitro can
induce a memory-like phenotype.When transferred into naïve
hosts, these cells have a resting phenotype, but produce more
IFNγ on cytokine restimulation, a response that remains de-
tectable 3 weeks after cell transfer [82]. Human NK cells have
similar properties, with a brief exposure to cytokines condi-
tioning enhanced responsiveness on rechallenge [83]. How
this memory-like state is established is a topic of investigation,
but epigenetic remodeling of a noncoding sequence at the
IFNG gene linked to increased IFN production can be induced
by in vitro cytokine priming [84]. Epigenetic programming
also underlies the sustained shifts in NK cell profiles that are
seen in human CMV (HCMV) infection. HCMV infection
drives expansion of a population of CD94-NKG2C NK cells
[85], and in the setting of hematopoietic stem cell transplan-
tation, this population has been demonstrated to have a
memory-like response to CMV [86]. The interaction between
HLA-E and CD94-NKG2C contributes to this expansion [87],
but additional pathways to NK memory in HCMV are also
operative, as evidenced by the FcεRIγ-deficient adaptive
NK cells that expand after activation through CD16 [16••].
HCMV infection is associated with sustained changes in NK
cell repertoire, distinct epigenetic profiles [15••, 16••], and
altered functional profiles [15••, 16••]. The responses appear
to be directed by exposure to the pathogen, in some cases
directly through a viral antigen, and in other cases through
secondary recognition of specific antibody. In congruence
with the findings in HCMV, an NK cell population that lacks
FcRγ expression and has enhanced ADCC activity was iden-
tified in HIV-infected subjects, with some features shared with
the memory-like population induced by CMV and some
unique surface receptor characteristics [88]. These findings
have compelling links to both the biology of adaptive immune
responses and the growing field of research in innate training
and tolerance whereby epigenetic programs direct altered sec-
ondary responses after an initial exposure [14, 89], and both
pathways can be harnessed towards goals of HIV prevention
and cure.
NK Cell Editing of Adaptive Immunity
Recent studies have focused attention on a critical role for NK
cells in the shaping adaptive immune responses. In MCMV
infection, NK cells rapidly eliminate infected targets, limiting
the type I interferon response, preserving conventional den-
dritic cells and CD8 T cell responses [90]. In this infection,
NK cells limit exposure of CD4 and CD8 T cells to infected
dendritic cells shaping the subsequent adaptive response [91]
and importantly, also limit tissue site T cell-mediated pathol-
ogy [92]. In HIV, NK cell editing of dendritic cells is aberrant
in the context of chronic inflammation and elevated IL-10,
leading to poorly dendritic cells with limited immunogenicity
[93]. Similarly, NK cells dictate immune response character-
is t ics in an indirect fashion in the lymphocyt ic
choriomeningitis virus (LCMV) mouse model. In this system,
NK cells have no significant role in elimination of virus-
infected targets, but they eliminate activated CD4 T cells ei-
ther limiting immunopathology, or contributing to exhaustion
and inefficient CD8 T cell control in chronic infection
[94–96]. NK cells have also been shown to shape the induc-
tion of antibody; perforin-mediated elimination of T follicular
helper (Tfh) cells in the lymph node by NK cells in acute
infection was shown to disrupt germinal center formation,
limiting immune memory development [97••]. Tfh cells have
been identified as the dominant population supporting repli-
cation and virus production in viremic HIV-1 infection [98],
and are likely a significant contributor to the HIV-1 reservoir.
The context-dependent effects of NK cells on adaptive im-
munity highlight the need for careful direction of efforts to
harness their activity in HIV infection. Specifically, disabling
their CD4 suppressive effects after vaccination may promote
more breadth of antibody response. In contrast, during acute
infection, enhancing NK-mediated elimination of Tfh cells
may limit the size of the reservoir that is established.
Likewise, during a curative intervention, unleashing NK cell
targeting of Tfh cells could again lead to reservoir reduction.
Directed recruitment of NK cells to lymph nodes also offers a
pathway to increase their efficacy [99]. The impact of NK
cells on interventions targeting adaptive responses offers a
novel pathway to enhance efforts at prevention and cure [3].
Conclusions
NK cells have emerged as multifunctional effector cells with
the potential to control infections and shape adaptive immune
responses. NK cells exert immune pressure on HIV and con-
tribute to protective vaccine responses and some phenotypes
of immune control. Significantly, there has been little effort to
optimize, direct, or specifically target NK cells in therapeutic
and preventative interventions. Mounting evidence from basic
biological studies of NK cells points to themultiple avenues to
enhance their antiviral and immunomodulatory function in
HIV. The barrier to eliciting effective immunity to HIV is
significant, and the potential to harness this important and
potent effector population must be a high-priority component
of research efforts in prevention and cure.
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